文献速递胸部肿瘤

ERBB2激活突变及其共发基因组改变促成ERBB2突变肺癌的疾病异质性

ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2026-04-01

该研究基于AACR GENIE和Flatiron Health-Foundation Medicine两个独立队列,比较了NSCLC中ERBB2酪氨酸激酶域(TKD)、细胞外域(ECD)及跨膜域-近膜域(TMD-JMD)突变的临床基因组特征。结果显示ECD突变患者多为男性、鳞癌及吸烟者,且肿瘤突变负荷更高、共突变更频繁;

要点

  • ERBB2突变NSCLC中TKD突变占多数,ECD和TMD-JMD突变比例较低但特征独特
  • ECD突变与男性、鳞癌、吸烟史及更高TMB和EGFR/KRAS/STK11/KEAP1/SMARCA4共突变相关
  • 一线化疗免疫治疗下ECD突变者12个月PFS率高于TKD突变者(35% vs 18%)

核心结论

  • 携带ECD-ERBB2突变的NSCLC具有独特的临床基因组表型,且一线化疗免疫治疗结局更优。

研究设计与样本

  • 研究纳入两个独立队列:AACR Project GENIE数据库(483例)和Flatiron Health-Foundation Medicine晚期NSCLC临床基因组数据库(286例)。
  • 比较TKD、ECD及TMD-JMD ERBB2突变患者的临床基因组特征,并评估化疗免疫治疗结局。

主要发现

  • 两个队列中TKD突变占比最高(75%和71%),其次为ECD(18%和24%)和TMD-JMD(7%和5%)。
  • ECD突变患者更常见男性(p<0.05)、鳞癌(p=0.0001和p=0.0002)及吸烟史(p=0.01和p<0.0001)。
  • GENIE队列中ECD突变较TKD突变有更高中位肿瘤突变负荷(p<0.0001)及EGFR、KRAS、STK11、KEAP1、SMARCA4共突变率(均p<0.0001)。
  • TMD-JMD突变肿瘤中PIK3CA共突变率24%,RBM10共突变率18%。

临床怎么用

  • 对ERBB2突变NSCLC应区分突变域(TKD、ECD、TMD-JMD),ECD突变者可能从一线化疗免疫治疗中获益更多。
  • ECD突变患者常伴鳞癌、吸烟史及特定共突变,治疗决策时需综合考虑这些特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: ERBB2 mutations occur in 1% to 4% of all NSCLCs. Trastuzumab-deruxtecan and the novel ERBB2 tyrosine kinase inhibitors zongertinib and sevabertinib are approved by the Food and Drug Administration for the treatment of metastatic ERBB2-mutant NSCLC based on data from tumors harboring tyrosine kinase domain (TKD) mutations. The clinico-genomic characteristics of NSCLC tumors with ERBB2 mutations beyond the TKD remain largely unexplored. METHODS: Patients with NSCLC with oncogenic ERBB2 mutations included in two independent cohorts (American Association for Cancer Research Project GENIE database and the U.S.-based deidentified Flatiron Health-Foundation Medicine advanced NSCLC Clinico-Genomic Database [FH]) were studied. The clinico-genomic characteristics of patients with tumors harboring TKD, extracellular domain (ECD), or transmembrane domain (TMD)-juxtamembrane domain (JMD) ERBB2 mutations were compared, and clinical outcomes with chemoimmunotherapy were evaluated. RESULTS: A total of 483 patients (GENIE [Genomics Evidence Neoplasia Information Exchange] cohort) and 286 patients (FH cohort) with ERBB2-mutant NSCLC were included. In both cohorts, most patients had tumors harboring TKD (75% and 71%), followed by ECD (18% and 24%) and TMD-JMD mutations (7% and 5%). In both cohorts, male patients (p < 0.05), patients with squamous NSCLC tumors (p = 0.0001 and p = 0.0002), and patients with a smoking history (p = 0.01 and p < 0.0001) were more likely to have ECD-mutant tumors. In the GENIE cohort with detailed genomic information available, ECD- versus TKD-mutant tumors had a higher median tumor mutation burden (p < 0.0001) and higher rates of co-mutations in EGFR (p < 0.0001), KRAS (p < 0.0001), STK11 (p < 0.0001), KEAP1 (p < 0.0001), and SMARCA4 (p < 0.0001). TMD-JMD-mutant tumors had high rates of PIK3CA (24%) and RBM10 (18%) co-mutations. In the FH cohort with detailed outcome data available, among patients with advanced ERBB2-mutant NSCLC treated with first-line chemoimmunotherapy, those with ECD-mutant tumors had longer 12-month progression-free survival compared with those with TKD mutations (35% versus 18%; hazard ratio, 0.72; confidence interval, 0.54-0.94, p = 0.026). This difference persisted in a multivariate Cox regression model accounting for other variables. CONCLUSION: NSCLCs harboring ECD-ERBB2 mutations are associated with a unique clinico-genomic phenotype and improved outcomes with first-line chemoimmunotherapy. These findings have implications for optimizing treatment strategies in this disease.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Stockhammer P, El Zarif T, Schillo JL, et al. ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer. J Thorac Oncol. 2026. PMID: 41932614. doi:10.1016/j.jtho.2026.103708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。